TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05545761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
Study: NCT05681962

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
Study: NCT05095818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP-RN
Description: Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
Study: NCT05916326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
Description: Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
Description: Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular injection of placebo in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular injection of placebo in the deltoid muscle of the upper arm
Study: NCT06115733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib、Capecitabine Tablets
Description: Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression.
Study: NCT05356858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: zanubrutinib orally, 80mg bid for 1 year
Study: NCT05227742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive oral psilocybin once per week for 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive oral psilocybin once per week for 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive oral psilocybin once per week for 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive inert placebo once per week for 5 weeks.
Study: NCT05656950

Intervention type: PROCEDURE
Intervention: Assessment
Description: Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
Study: NCT05761860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone 5mg oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone 5mg oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 2.5 mg Oral Tablet
Description: Oxycodone 2.5mg oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 2.5 mg Oral Tablet
Description: Oxycodone 2.5mg oral administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oxyCODONE Oral Tablet
Description: Oxycodone 0mg (placebo) oral administration

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo oxyCODONE Oral Tablet
Description: Oxycodone 0mg (placebo) oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Nasal Spray (48 IU)
Description: Intranasal oxytocin administration (48 IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Nasal Spray (48 IU)
Description: Intranasal oxytocin administration (48 IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Nasal Spray (48 IU)
Description: Intranasal oxytocin administration (48 IU)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxytocin Nasal Spray
Description: Intranasal oxytocin placebo administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxytocin Nasal Spray
Description: Intranasal oxytocin placebo administration

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Oxytocin Nasal Spray
Description: Intranasal oxytocin placebo administration
Study: NCT05637840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: Collection of 36-84 urine samples over a 14 consecutive day period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: Collection of 36-84 urine samples over a 14 consecutive day period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
Study: NCT04763902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE) Schedule
Description: \[See arm/group descriptions\]
Study: NCT05964140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Study: NCT05218889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib + camrelizumab + nab-paclitaxel + S-1
Description: phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel + gemcitabine
Description: nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
Study: NCT06226246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROS VR CPR training program
Description: HEROS VR training program which combined video training and VR session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional HEROS CPR training program
Description: Conventional HEROS training program using video learning
Study: NCT05215587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEVAR
Description: A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
Study: NCT05887765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,1mg/kg Dexamethasone
Description: administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
Study: NCT06297590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3954068
Description: Administered IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3954068
Description: Administered IT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flortaucipir F18
Description: Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flortaucipir F18
Description: Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
Study: NCT06151964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9550
Description: Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9550
Description: Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9550
Description: Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9550
Description: Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching administration volumes for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching administration volumes for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching administration volumes for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching administration volumes for SC injection
Study: NCT06536530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame-Based Training
Description: 40-50 min sessions, two sessions per week, for a total of eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Based Training
Description: 40-50 min sessions, two sessions per week, for a total of eight weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-List
Description: Participants will not train with any program and they will not assist to any specific session or intervention
Study: NCT05887765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,2mg/kg Dexamethasone
Description: administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
Study: NCT06568432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP+SAA POCT
Description: CRP+SAA POCT will be provided in 20 village clinics in the intervention group
Study: NCT06265428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Administered I.V.
Study: NCT06128109

Intervention type: DEVICE
Group type: OTHER
Intervention: Thioderm Strong
Description: Test Device

Intervention type: DEVICE
Group type: OTHER
Intervention: Thioderm Strong
Description: Test Device

Intervention type: DEVICE
Group type: OTHER
Intervention: Juvéderm VOLUMA Lidocaine
Description: Comparator Device

Intervention type: DEVICE
Group type: OTHER
Intervention: Juvéderm VOLUMA Lidocaine
Description: Comparator Device
Study: NCT06536374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim Tablets
Description: Trimethoprim 150mg is administered once daily for 3 months
Study: NCT05983133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-EGFRd2
Description: Given into the vein (IV; intravenously)
Study: NCT06454747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-030 gel 0.64%
Description: Topical application to face twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Topical application to face twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-030 gel 0.08%
Description: Topical application to face twice daily for 12 weeks.
Study: NCT06265727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-701
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)
Study: NCT05166109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
Study: NCT05848297

Intervention type: DEVICE
Intervention: Transcranial Doppler ultrasonography (TCD)
Description: Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
Study: NCT06185764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-670
Description: Solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-670
Description: Solution for intravenous administration.
Study: NCT05528796

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Description: The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family.
Study: NCT06185764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for intravenous administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for intravenous administration.
Study: NCT06649292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904
Description: SHR-A1904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Docetaxel, Irinotecan
Description: Paclitaxel, Docetaxel, Irinotecan
Study: NCT06198010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive enhanced usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive enhanced usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive ASCENT guide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive ASCENT guide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Attend video or phone calls with a CHW and/or PCM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Pain Management
Description: Receive personalized pain management plan
Study: NCT06462482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Study: NCT05374980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Drink a bottle of 200ml yogurt every morning and evening for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink a bottle of 200ml placebo every morning and evening for 8 weeks
Study: NCT06085248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subject-specific optimized RAS
Description: Walking with metronome-based RAS cueing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active walking
Description: walking without RAS cue

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active walking
Description: walking without RAS cue
Study: NCT05742256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 1mg/kg
Description: Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml